Track topics on Twitter Track topics that are important to you
The renal diseases therapy area encompasses a range of diseases of the kidney, such as chronic kidney disease CKD, acute kidney injury, diabetic nephropathy and focal segmental glomerulosclerosis. Renal diseases are becoming increasingly common due to the increased prevalence of hypertension and diabetes, two major causes of CKD. For most forms of renal diseases, early detection and management may slow down or prevent progression to renal failure and associated complications. However, many renal diseases are typically asymptomatic until they have progressed to endstage renal disease ESRD, which requires renal replacement therapies such as hemodialysis and renal transplantation, and is associated with substantial morbidity and mortality.
The marketed treatments of renal diseases typically focus on controlling the risk factors and complications of renal failure. Treatments include antihypertensive agents, hormones, antibiotics, and immunosuppressants. However, these treatments are often not wholly effective, as patients are still at risk of dying prematurely from cardiovascular disease or progressing to ESRD. Few new renal disease therapies have reached the market in the past decade, and with the rising prevalence, there is a high need for innovation and investment in the renal diseases therapy area.
The report assesses firstinclass innovation in the renal diseases pipeline, highlighting key trends and emerging treatment classes. There are 100 firstinclass products in development in this therapy area, which account for 39% of products in the overall pipeline for which there is a disclosed molecular target, and act upon 77 unique individual molecular targets. Firstinclass innovation is concentrated heavily at the early drug development stages.
The firstinclass programs identified show considerable diversity, and the relatively high degree of innovation in the renal diseases therapy area makes for a promising development pipeline. It is clear that recent activity in this area has increased, partly owing to the growing recognition of the unmet medical need. Further investment in innovation would benefit the therapy area greatly, and likely prove a worthwhile investment, particularly for highly prevalent diseases such as CKD and diabetic nephropathy, for which there are a lack of effective pharmacotherapeutic options.
With 365 products in active development, the pipeline is modestly sized. Does current pipeline innovation hold the potential to affect the future renal diseases market?
There are 100 firstinclass products in the renal diseases pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
The majority of firstinclass products were in development for indications involving inflammation. Which firstinclass targets are most promising, and how does the ratio of firstinclass targets to firstinclass products differ by stage of development and molecular target class?
A significant number of firstinclass products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which firstinclass programs have not yet been involved in a licensing or codevelopment deal?
Reasons to buy
Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
Visualize the composition of the renal diseases market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
Analyze the renal diseases pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating renal diseases to overcome the level of unmet need.
Assess the therapeutic potential of firstinclass targets. Using proprietary matrices, firstinclass products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: renal failure, glomerulonephritides, and renal scarring. Promising targets have been reviewed in greater detail.
Identify commercial opportunities in the renal diseases deals landscape by analyzing trends in licensing and codevelopment deals, and producing a list of firstinclass therapies with no prior involvement in licensing or codevelopment deals
Original Article: Frontier Pharma: Renal Diseases High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease [Report Updated: 03102017] Prices from USD $6995NEXT ARTICLE
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experi...
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...